Clinical Trials
12 trialsNCT05286814 2026-05-04
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03604198 2026-04-21
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Corcept Therapeutics
Phase 2 Active not recruiting
NCT06006013 2026-02-18
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Emory University
Phase 2 Recruiting
NCT02721732 2026-01-29
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03370718 2024-12-10
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03612232 2024-08-19
CaboACC
Wuerzburg University Hospital
Phase 2 Unknown
NCT02468193 2020-05-06
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
Novartis
Phase 2 Completed
NCT02804750 2019-10-15
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Corcept Therapeutics
Phase 2 Completed
NCT02720484 2019-05-01
Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer
Northwestern University
Phase 2 Terminated
NCT00215202 2018-05-17
Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT01255137 2013-06-27
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00071058 2012-09-18
Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed